4DMedical Limited (ASX:4DX) shares fell 4.64% to $4.11 on 21 September 2026, despite recently delivering what the company itself describes as its most significant commercial year to date. 4DMedical (ASX:4DX), a global leader in AI-powered respiratory imaging technology, reported FY26 Operating Revenue up 21% to $7.1 million, a 77% jump in scan volumes, and closed the year with $278 million in cash following its flagship CT:VQ product achieving FDA clearance, Medicare reimbursement, and commercial deployment across six regulatory jurisdictions. With a share price move that appears disconnected from a genuinely transformational year of regulatory and commercial progress, investors may be weighing near-term cash burn and adjusted losses against the company's long-term addressable market opportunity.

Latest Development

The centrepiece of 4DMedical's FY26 result was the commercialisation of CT:VQ, the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology. The product received FDA clearance in September 2025, with the US Centers for Medicare & Medicaid Services confirming reimbursement of US$650.50 per scan within days. By 30 June 2026, CT:VQ had been adopted commercially by five major US Academic Medical Centers — Stanford, Cleveland Clinic, UC San Diego Health, University of Miami and University of Chicago Medicine — all operating under full commercial terms.

The company also entered a three-year commercial agreement with SimonMed Imaging, a 170-site outpatient radiology network across 10 states, on full commercial terms with no evaluation phase — a milestone 4DMedical's CEO described as validation that 'the argument had already been won' at the academic institutions that set the clinical standard. Separately, an expanded distribution agreement with Philips will see CT:VQ distributed across US and Canadian healthcare systems, underwritten by a minimum order commitment over CY26 and CY27.

Regulatory approvals expanded to six jurisdictions during the year, including European CE Mark certification in March 2026, UK certification in April 2026, and Australian TGA approval in June 2026, which was followed within days by paid commercial contracts with multiple Australian imaging providers. The company also launched CLEAR, a clinical evidence program targeting the acute pulmonary embolism market, which management says lifts the total addressable US market for CT:VQ to approximately US$3 billion.

Financially, FY26 operating revenue rose 21% to $7.1 million with gross margins exceeding 90%, while the adjusted net loss narrowed 7% to $32.9 million. The statutory result included a non-cash expense of $164.6 million related to Fair Value remeasurement of the Equity component of the Pro Medicus funding Facility — a charge that involves no cash outflow and does not reflect operating performance. The company closed the year with $278 million in cash, following a $150 million institutional Placement in January 2026 and an $83 million placement in March 2026, and was included in the S&P/ASX 200 index in April 2026.

Sector Context

4DMedical operates in the medical imaging and diagnostics technology sector, a segment that combines the long regulatory and commercialisation timelines typical of healthcare technology with the scalability of a software-as-a-service Business model once approvals are secured. The company's SaaS-based delivery model, with gross margins exceeding 90%, sits at the more capital-efficient end of the MedTech spectrum, though revenue remains small relative to the company's substantial cash reserves and ongoing Investment in commercialisation.

Healthcare technology stocks generally trade on a combination of regulatory milestones, commercial traction metrics such as site growth and scan volumes, and the size of the addressable market opportunity, rather than on near-term profitability — a dynamic clearly at play in 4DMedical's case, where the company remains loss-making by design while it builds out its US and European commercial footprint. The sector can also see sharp share price moves around single-day results even when the underlying trajectory is positive, given the market's focus on the pace of conversion from regulatory approval to recurring revenue.

Risks

  • Ongoing cash burn, with an adjusted net loss of $32.9 million in FY26, meaning continued reliance on the company's cash reserves or further Capital raisings to fund the path to profitability.
  • Execution risk in converting regulatory approvals and signed commercial agreements into sustained, growing scan volumes and Recurring Revenue across multiple new markets simultaneously.
  • Reimbursement risk, as CT:VQ's commercial model depends on continued and expanding payer reimbursement, particularly as the company pursues Medicare Benefits Schedule reimbursement in Australia and broader coverage for the CLEAR pulmonary embolism indication in the US.
  • Competitive and technology risk in a medical imaging AI sector that continues to attract new entrants and where 4DMedical's differentiated position could face pressure over time.
  • Integration risk associated with the 2026 Acquisition of contextflow and partnerships with RevealDx and Azra AI, which need to be successfully woven into a single commercial and clinical workflow.

What to Watch Ahead

  • Conversion of the SimonMed and Philips agreements into first patient scanning and revenue recognition, both flagged as imminent at the time of the results.
  • Progress of the CLEAR clinical evidence program in the acute pulmonary embolism market, including further site additions such as the discussed European KOL centre.
  • Site and scan Volume growth in FY27, building on the 540 global sites and 344,075 scans reported for FY26.
  • Full commercial launch of the fourth AI Lab-style product referenced in the Hotwire-style FY27 guidance context, and progress on Medicare Benefits Schedule reimbursement pursuit in Australia.
  • Trends in adjusted net loss and cash balance, as investors assess the company's runway relative to its stated FY27 focus on 'conversion' from thought Leadership to at-scale volume.

The Bottom Line

4DMedical (ASX:4DX) delivered what its own CEO called the year its lead product 'reached the market' — moving from an FDA submission at the start of FY26 to authorisation in six countries, commercial adoption by five leading US academic medical centres, and a national outpatient network agreement, all by year end. The 4.64% share price fall on results day sits somewhat awkwardly against that backdrop, though it may reflect the market weighing the sizeable ongoing cash burn and statutory loss against the long runway still required to convert regulatory wins into meaningful revenue. For investors evaluating 4DMedical (ASX:4DX) after the pullback, the FY27 focus on 'conversion' — turning established regulatory access and commercial agreements into routine, at-scale scan volume — looks like the central metric to track.